TACSTD2 and cholangiocarcinoma: NIR-PIT utilizing anti-TROP2 antibody demonstrated specific cell killing against TROP2-expressing cells and the suppression of tumor growth in a xenograft model of pancreatic cancer and cholangiocarcinoma [169].